BioSpace News Archive

MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2022 on Thursday, March 16, 2023.

Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling reagents, and Fluoroprobes, a leader in fluorescent probes and dyes.

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023.

Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, was recently awarded a grant from Israel’s Ministry of Economy to encourage the Company’s marketing activities and enhance the commercialization of the LIBERTY Robotic System in the US market, within the scope of its ‘Smart Money’ program.

Debiopharm (www.debiopharm.com) today announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk.

Instead of special heart scans, physicians can use images of the chest captured months earlier, and for other reasons, to estimate patients’ risk of heart attack or death during several kinds of major surgeries, a new study shows.

Advantus Health Partners and GE HealthCare announced an agreement of up to $760M over 10-years to provide GE HealthCare’s Healthcare Technology Management services to Advantus Health Partners’ clients.

IgGenix, Inc., a pre-clinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, recently presented insights into the potential for IgE antibody re-engineering in shellfish allergy.

Capricor Therapeutics announced that the Company’s HOPE-2 study with lead asset, CAP-1002, for treating Duchenne muscular dystrophy has been named as a recipient of the Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award.

LanzaTech Global, Inc., has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2023.